In the first clinical trial of dose-adjusted EPOCH along with inotuzumab ozogamicin (InO) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), Fred Hutch Cancer Center researchers found this combination was well tolerated and produced a high overall response rate (83%). DA-EPOCH is a combination of the chemotherapy drugs etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin. InO is an antibody-drug conjugate, a form of immunotherapy that attempts to deliver chemotherapy directly to cancer cells via a monoclonal antibody. The study, published today in JAMA Oncology, also highlighted that side effects were similar to those commonly seen in people with B-ALL, making the regimen feasible to administer for community oncologists experienced in treating such patients.
